title: Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
abstract: Stroke prevention is central to the management of patients with atrial fibrillation (AF). Vitamin K antagonists (VKAs) are the established and long-standing option for stroke prevention therapy in patients with AF. However, non-VKA oral anticoagulants (NOACs) have recently been developed and demonstrated non-inferior efficacy vs VKA treatment, with fewer limitations in clinical practice and with reduced risks of major bleeding. In order to discuss the usage, efficacy and safety of NOACs, a satellite symposium was held at the Cardiostim/ EHRA Europace Congress in Nice in June 2014. At present, three NOACs, a direct thrombin inhibitor (dabigatran) and two direct factor Xa inhibitors (rivaroxaban and apixaban) have been approved in Europe for stroke prevention in patients with AF. In addition, the once-daily factor Xa inhibitor edoxaban has recently been evaluated in this setting in the phase III Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis In Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48) that compared edoxaban 30 mg once daily (low-dose regimen) with dose-adjusted warfarin (international normalised ratio 2.0-3.0). ENGAGE AF-TIMI 48 was the largest trial with a NOAC to date, and demonstrated that both dosing regimens of once-daily edoxaban were non-inferior to well-managed warfarin treatment for the prevention of stroke or systemic embolism and also provided significant reductions in the risk of haemorrhagic stroke, cardiovascular mortality, major bleeding and intracranial bleeding. In summary, the recent availability of NOACs has enabled physicians to avoid the limitations of VKA therapy in clinical practice and tailor anticoagulant treatment to the individual patient. However, worldwide usage of oral anticoagulant therapy remains suboptimal compared with guideline recommendations, and further dissemination of its benefits may prove helpful.
authors.affiliation: Medical Writer, Radcliffe Cardiology;
authors.forename: Katrina
authors.initials: K
authors.lastname: Mountfort
authors.affiliation: St. George's University Hospital, London, UK;
authors.forename: John
authors.initials: J
authors.lastname: Camm
authors.affiliation: University of Birmingham, Birmingham, UK;
authors.forename: Gregory
authors.initials: G
authors.lastname: Lip
authors.affiliation: St Vincenz-Hospital, Paderborn, Germany;
authors.forename: Andreas
authors.initials: A
authors.lastname: Goette
authors.affiliation: Georges Pompidou European Hospital and Paris Descartes University, Paris, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Le Heuzey
keywords: NOAC; Non-VKA oral anticoagulant; atrial fibrillation; stroke prevention in atrial fibrillation; vitamin K antagonist
references.citation: Ann Intern Med. 1999 Oct 5;131(7):492-501
references.pmid: 10507957
references.citation: JAMA. 2001 May 9;285(18):2370-5
references.pmid: 11343485
references.citation: Heart Rhythm. 2007 Mar;4(3 Suppl):S1-6
references.pmid: 17336876
references.citation: Lancet. 2007 Aug 11;370(9586):493-503
references.pmid: 17693178
references.citation: Cardiol Clin. 2008 May;26(2):169-87, v-vi
references.pmid: 18406993
references.citation: J Interv Card Electrophysiol. 2008 Aug;22(2):129-37
references.pmid: 18425569
references.citation: Chest. 2008 Jun;133(6 Suppl):160S-198S
references.pmid: 18574265
references.citation: Stroke. 1991 Aug;22(8):983-8
references.pmid: 1866765
references.citation: Stroke. 2009 Jan;40(1):235-40
references.pmid: 18757287
references.citation: Lancet. 2009 Aug 15;374(9689):534-42
references.pmid: 19683639
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: Thromb Haemost. 2010 Sep;104(3):633-41
references.pmid: 20694273
references.citation: Am Heart J. 2010 Oct;160(4):635-41
references.pmid: 20934556
references.citation: Rev Port Cardiol. 2010 Jul-Aug;29(7-8):1207-17
references.pmid: 21072908
references.citation: N Engl J Med. 2011 Sep 8;365(10):883-91
references.pmid: 21830957
references.citation: N Engl J Med. 2011 Sep 15;365(11):981-92
references.pmid: 21870978
references.citation: Am Heart J. 2012 Jan;163(1):13-19.e1
references.pmid: 22172431
references.citation: Pharmacotherapy. 2012 Mar;32(3):285-96
references.pmid: 22392459
references.citation: Eur Heart J. 2012 Nov;33(21):2719-47
references.pmid: 22922413
references.citation: Clin Drug Investig. 2012 Nov;32(11):771-7
references.pmid: 23018284
references.citation: Circulation. 2013 Feb 12;127(6):720-9
references.pmid: 23325525
references.citation: Europace. 2013 May;15(5):625-51
references.pmid: 23625942
references.citation: PLoS One. 2013 May 21;8(5):e63479
references.pmid: 23704912
references.citation: Europace. 2014 Jan;16(1):6-14
references.pmid: 24084680
references.citation: N Engl J Med. 2013 Nov 28;369(22):2093-104
references.pmid: 24251359
references.citation: Clin Cardiol. 2014 Jan;37(1):32-47
references.pmid: 24254991
references.citation: Lancet. 2014 Mar 15;383(9921):955-62
references.pmid: 24315724
references.citation: Lancet. 2014 Mar 15;383(9921):931-3
references.pmid: 24315725
references.citation: Thromb Haemost. 2014 Mar 3;111(3):465-73
references.pmid: 24337399
references.citation: Europace. 2014 Mar;16(3):308-19
references.pmid: 24351881
references.citation: Circulation. 2014 Apr 15;129(15):1568-76
references.pmid: 24463370
references.citation: Am Heart J. 2014 Mar;167(3):329-34
references.pmid: 24576516
references.citation: Thromb Haemost. 2014 May 5;111(5):833-41
references.pmid: 24651882
references.citation: J Am Geriatr Soc. 2014 May;62(5):857-64
references.pmid: 24786913
references.citation: Chest. 2014 May;145(5):1177-1178
references.pmid: 24798856
references.citation: Eur Heart J. 2014 Jul 21;35(28):1844-55
references.pmid: 24810388
references.citation: Circulation. 2014 Jun 10;129(23):2371-9
references.pmid: 24842943
references.citation: Eur Heart J. 2014 Jun 7;35(22):1422
references.pmid: 25035872
references.citation: Arch Intern Med. 1996 Dec 9-23;156(22):2537-41
references.pmid: 8951296